Pacer Advisors Inc. lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 0.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 243,545 shares of the biotechnology company’s stock after acquiring an additional 1,673 shares during the quarter. Pacer Advisors Inc. owned approximately 0.57% of United Therapeutics worth $144,417,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the business. Geneos Wealth Management Inc. grew its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 70 shares during the last quarter. Jump Financial LLC acquired a new stake in United Therapeutics during the second quarter worth approximately $277,000. Cerity Partners LLC boosted its holdings in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after acquiring an additional 5,600 shares during the period. Finally, Bank of Nova Scotia boosted its holdings in shares of United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 105 shares during the period. Institutional investors own 94.08% of the company’s stock.
Insider Buying and Selling
In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,921,276.08. The trade was a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 483,333 shares of company stock valued at $268,126,647. 8.60% of the stock is owned by company insiders.
Analysts Set New Price Targets
Read Our Latest Stock Report on UTHR
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $517.71 on Monday. The company has a market cap of $21.98 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 1.73 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The stock has a fifty day moving average price of $543.63 and a 200-day moving average price of $532.79.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.63 EPS. Research analysts predict that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
- Five stocks we like better than United Therapeutics
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
